This would increase intratumoral drug perfusion, while concurrently impeding the adaptive fitness of tumour and stromal cells to survive under hypoxic conditions (via HIF-1α) and thus promote widespread hypoxic necrosis. The gene discussed is HIF1A; the disease is neoplasm.